FR2215233B1 - - Google Patents

Info

Publication number
FR2215233B1
FR2215233B1 FR7402823A FR7402823A FR2215233B1 FR 2215233 B1 FR2215233 B1 FR 2215233B1 FR 7402823 A FR7402823 A FR 7402823A FR 7402823 A FR7402823 A FR 7402823A FR 2215233 B1 FR2215233 B1 FR 2215233B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7402823A
Other versions
FR2215233A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferrosan ApS
Original Assignee
Ferrosan ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9778288&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR2215233(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrosan ApS filed Critical Ferrosan ApS
Publication of FR2215233A1 publication Critical patent/FR2215233A1/fr
Application granted granted Critical
Publication of FR2215233B1 publication Critical patent/FR2215233B1/fr
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
FR7402823A 1973-01-30 1974-01-29 Expired FR2215233B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB449673A GB1422263A (en) 1973-01-30 1973-01-30 4-phenyl-piperidine compounds

Publications (2)

Publication Number Publication Date
FR2215233A1 FR2215233A1 (fr) 1974-08-23
FR2215233B1 true FR2215233B1 (fr) 1977-01-28

Family

ID=9778288

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7402823A Expired FR2215233B1 (fr) 1973-01-30 1974-01-29

Country Status (20)

Country Link
US (2) US3912743A (fr)
JP (2) JPS5946216B2 (fr)
AT (1) AT333759B (fr)
BE (1) BE810310A (fr)
CA (1) CA1038390A (fr)
CH (1) CH592059A5 (fr)
DE (1) DE2404113C2 (fr)
DK (1) DK149843C (fr)
ES (2) ES422734A1 (fr)
FI (1) FI57932C (fr)
FR (1) FR2215233B1 (fr)
GB (1) GB1422263A (fr)
HK (1) HK13081A (fr)
IE (1) IE38801B1 (fr)
IT (1) IT1054157B (fr)
LU (2) LU69264A1 (fr)
NL (2) NL179187C (fr)
NO (1) NO144568C (fr)
PH (1) PH10383A (fr)
SE (1) SE401827B (fr)

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3800378A (en) * 1972-06-07 1974-04-02 Rca Corp Method of making a directly-heated cathode
US4442113A (en) * 1981-05-07 1984-04-10 A/S Ferrosan Long-term weight reduction of obese patients using femoxetine
US4485109A (en) * 1982-05-07 1984-11-27 E. I. Du Pont De Nemours And Company 4-Aryl-4-piperidinecarbinols
DK149624C (da) * 1983-03-07 1987-02-02 Ferrosan As Fremgangsmaade til fremstilling af (+)-trans-3-((4-methoxyphenoxy)-methyl)-1-methyl-4-phenylpiperidin eller et farmaceutisk acceptabelt salt heraf ud fra en blanding af enantiomererne
US4593036A (en) * 1984-02-07 1986-06-03 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-[(4-methoxyphenoxy)methyl]-1-methylpiperidine useful as 5-HT potentiator
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (fr) * 1984-12-13 1987-05-27 Beecham Group Plc Dérivés de la pipéridine à activité gastro-intestinale
DE3680184D1 (de) * 1985-08-10 1991-08-14 Beecham Group Plc Verfahren zur herstellung von arylpiperidincarbinol.
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
NO158038C (no) * 1985-10-21 1988-06-29 Standard Tel Kabelfab As Kabel.
ES2058061T3 (es) * 1985-10-25 1994-11-01 Beecham Group Plc Derivado de piperidina, su preparacion y su uso como medicamento.
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
US5017585A (en) * 1986-11-03 1991-05-21 Novo Nordisk A/S Method of treating calcium overload
DK231088D0 (da) * 1988-04-28 1988-04-28 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
DK588289D0 (da) * 1989-11-22 1989-11-22 Ferrosan As Ny heterocyklisk kemi
DK640289D0 (da) * 1989-12-18 1989-12-18 Ferrosan As Ny heterocyklisk kemi
IL98757A (en) * 1990-07-18 1997-01-10 Novo Nordisk As Piperidine derivatives their preparation and pharmaceutical compositions containing them
JPH06502854A (ja) * 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
DE4112353A1 (de) * 1991-04-16 1992-10-22 Basf Ag 1,3,4-trisubstituierte piperidin-derivate, ihre herstellung und verwendung
US5512584A (en) * 1991-04-16 1996-04-30 Basf Aktiengesellschaft 1,3,4-trisubstituted piperidine derivatives, the preparation and use thereof
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
GB9305175D0 (en) * 1993-03-13 1993-04-28 Smithkline Beecham Plc Novel process
US5276042A (en) * 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
EP0639568A1 (fr) * 1993-08-19 1995-02-22 Novo Nordisk A/S Dérivés de pipéridine, leur préparation et leur utilisation dans le traitement des maladies neurodégénératives
US5446057A (en) * 1993-09-24 1995-08-29 Warner-Lambert Company Substituted tetrahydropyridine and piperidine carboxylic acids as muscarinic antagonists
US20020086053A1 (en) * 1993-12-15 2002-07-04 Smithkline Beecham Plc Formulations, tablets of paroxetine and process to prepare them
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
ES2102295B1 (es) * 1994-03-18 1998-04-01 Ferrer Int Nuevos compuestos derivados de la n-benzoilmetil-piperidina.
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
WO1996036636A1 (fr) * 1995-05-17 1996-11-21 Novo Nordisk A/S Procede de preparation de derives de 4-arylpiperidine
US6548084B2 (en) * 1995-07-20 2003-04-15 Smithkline Beecham Plc Controlled release compositions
EP0759299B1 (fr) * 1995-08-16 2000-04-26 Eli Lilly And Company Potentialisation de la sérotonine
DE59610509D1 (de) * 1995-09-07 2003-07-10 Hoffmann La Roche Neue 4-(oxyalkoxyphenyl)-3-oxy-piperidine zur behandlung von herz- und niereninsuffizienz
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
GB9605828D0 (en) * 1996-03-20 1996-05-22 Smithkline Beecham Plc Treatment method
ES2121685B1 (es) * 1996-04-10 1999-09-16 Vita Invest Sa Procedimiento para la obtencion de (+)-trans-4(4-fluoro-fenil)-3-hidroximetil-1-metilpiperidina.
JP3446468B2 (ja) 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (fr) * 1996-05-30 1997-11-30 Shu-Zhong Wang Methode de preparation de chlorhydrate de paroxetine amorphe
JP3882224B2 (ja) 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP0812827B1 (fr) * 1996-06-13 2009-09-02 Sumitomo Chemical Company, Limited Dérivés de pipéridine comme intermédiaire pour la production de paroxétine et procédé pour leur préparation
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US5672612A (en) * 1996-09-09 1997-09-30 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
GB9623359D0 (en) * 1996-11-09 1997-01-08 Smithkline Beecham Plc Novel process
GB9700690D0 (en) * 1997-01-15 1997-03-05 Smithkline Beecham Plc Novel process
ES2329739T3 (es) 1997-04-07 2009-11-30 Georgetown University Analogos de cocaina.
GB9710004D0 (en) 1997-05-17 1997-07-09 Knoll Ag Chemical process
ATE279393T1 (de) 1997-05-29 2004-10-15 Smithkline Beecham Corp Neues verfahren
CN1092654C (zh) * 1997-06-10 2002-10-16 斯索恩有限公司 4－苯基哌啶类化合物
WO1998056787A1 (fr) 1997-06-10 1998-12-17 Synthon B.V. Composes 4-phenylpiperidine
CA2212451C (fr) * 1997-08-07 2001-10-02 Brantford Chemicals Inc. Preparation stereoselective et utile de 4-arylpiperidines substituees en position 3
ES2137131B1 (es) * 1998-02-06 2000-09-16 Vita Invest Sa Derivado de piperidinona procedimiento de obtencion y procedimiento para su utilizacion.
CA2323896A1 (fr) * 1998-03-16 1999-09-23 Andrew Simon Craig Forme cristalline de la paroxetine
GB9806312D0 (en) * 1998-03-24 1998-05-20 Smithkline Beecham Plc Novel formulations
US6528529B1 (en) * 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
BR9909529A (pt) * 1998-04-09 2000-12-12 Smithkline Beecham Plc Maleato de paroxetina
GB9808896D0 (en) * 1998-04-25 1998-06-24 Smithkline Beecham Plc Novel compound
DE69910691T2 (de) 1998-06-29 2004-07-08 Sumika Fine Chemical Co. Ltd. L-Tartrate von Trans-(-)-4-(4-Fluorphenyl)-3-Hydroxymethyl-Piperidin Verbindungen und Verfahren zu ihrer Herstellung
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
ES2138937B1 (es) * 1998-07-07 2000-10-01 Medichem Sa Polimorfo de maleato de paroxetina y formulaciones farmaceuticas que lo contienen.
JP2002522434A (ja) * 1998-08-07 2002-07-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 非結晶性無水形のパロキセチン塩酸塩の製法
JP2002526528A (ja) 1998-10-07 2002-08-20 ジョージタウン ユニヴァーシティー 単量体およびニ量体の複素環、ならびにその治療的使用
GB9826242D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826178D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel process
GB9826171D0 (en) * 1998-11-30 1999-01-20 Smithkline Beecham Plc Novel compounds
EP1135383B1 (fr) * 1998-11-30 2003-12-03 SmithKline Beecham plc Solvates de paroxetine propan-2-ol melanges
GB9827387D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel process
JP2002533325A (ja) * 1998-12-22 2002-10-08 ペンテツク・フアーマシユーテイカルズ・インコーポレイテツド アリールピペリジンカルビノール中間体および誘導体の製造方法
GB9828767D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9914583D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
GB9915303D0 (en) * 1999-06-30 1999-09-01 Smithkline Beecham Plc Novel process
CA2341984A1 (fr) * 1999-07-01 2001-01-11 Paolo Mascagni Complexes de paroxetine, avec des cyclodextrines et des derives de la cyclodextrine
GB9915727D0 (en) * 1999-07-03 1999-09-08 Smithkline Beecham Plc Novel compound and process
GB9916187D0 (en) * 1999-07-09 1999-09-08 Smithkline Beecham Plc Novel process
GB9916392D0 (en) * 1999-07-13 1999-09-15 Smithkline Beecham Plc Novel process
IT1313702B1 (it) 1999-08-02 2002-09-09 Chemi Spa Processo per la preparazione di derivati 3-sostituiti di 4-fenil-piperidine.
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
GB9920147D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel process
GB9923540D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9923539D0 (en) * 1999-10-05 1999-12-08 Smithkline Beecham Plc Novel process
GB9924882D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel process
WO2001029002A1 (fr) * 1999-10-20 2001-04-26 Smithkline Beecham Plc Preparation d'esters de 4-(fluorophenyl)piperidine
GB9924855D0 (en) * 1999-10-20 1999-12-22 Smithkline Beecham Plc Novel processes
US6503927B1 (en) 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
US6380200B1 (en) 1999-12-07 2002-04-30 Pfizer, Inc. Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complications
HU226912B1 (en) * 2000-04-07 2010-03-01 Richter Gedeon Nyrt New paroxetin salt and medicament containing it
AU2000246280A1 (en) * 2000-05-12 2001-11-20 Synthon B.V. Tosylate salts of 4-(p-fluorophenyl)-piperidine-3-carbinols
US6833458B2 (en) 2000-06-05 2004-12-21 Development Center For Biotechnology Practical syntheses of chiral trans-3, 4-disubstituted piperidines and the intermediates
WO2002006275A1 (fr) * 2000-07-17 2002-01-24 Smithkline Beecham P.L.C. Nouveaux procedes de preparation de derives 4-phenylpiperidine
GB0021145D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
GB0021147D0 (en) * 2000-08-30 2000-10-11 Knoll Ag Chemical process
AU2001211337A1 (en) * 2000-10-06 2002-04-15 Smithkline Beecham Plc Process for the preparation of aryl-piperidine carbinols and intermediates thereof
WO2002032870A1 (fr) * 2000-10-20 2002-04-25 Smithkline Beecham P.L.C. Procede de preparation de composes de -4-aryle piperidine substitue en position 3
ES2232588T3 (es) * 2001-01-04 2005-06-01 Ferrer Internacional, S.A. Procedimiento pra la preparacion de (+-) - trans-4-p-fluorofenil -3- hidroximetil-1-metilpiperidina.
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6777554B2 (en) 2001-02-05 2004-08-17 Teva Pharmaceutical Industries Ltd. Preparation of N-methylparoxetine and related intermediate compounds
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
WO2002068416A2 (fr) * 2001-02-24 2002-09-06 Spurcourt Limited Procede de preparation de la paroxetine et intermediaires a cet usage
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
EP1406624A4 (fr) * 2001-06-13 2005-03-30 Teva Pharma Procede de preparation de paroxetine sensiblement exempte d'impuretes alcoxy
US20040225128A1 (en) * 2001-08-02 2004-11-11 Callewaert George Leo Paroxetine isethionate salt, process of preparation and use in the treatment of depression
ES2666188T3 (es) * 2001-10-12 2018-05-03 Azevan Pharmaceuticals, Inc. Antagonistas del v1a de vasopresina beta-lactámicos
AU2002330771A1 (en) * 2001-10-22 2003-06-10 Synthon B.V. N-formyl derivatives of paroxetine
AU2002360775B9 (en) * 2001-12-28 2008-07-24 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical formulation of paroxetine hydrochloride and a process for preparation thereof
US6956121B2 (en) 2002-03-01 2005-10-18 Teva Pharmaceutical Industries Ltd. Preparation of paroxetine involving novel intermediates
US7138523B2 (en) * 2002-05-16 2006-11-21 Apotex Pharmachem Inc. Preparation of 4-(4-fluorophenyl)-N-alkylnipecotinate esters, 4-(4-fluorophenyl)-N-arylnipecotinate esters and 4-(4-fluorophenyl)-N-aralkylnipecotinate esters
KR100477048B1 (ko) * 2002-07-05 2005-03-17 임광민 피페리딘 화합물의 새로운 제조방법
CA2502704A1 (fr) * 2002-11-01 2004-05-13 Neurosearch A/S Nouveaux derives de piperidine et leur utilisation en tant qu'inhibiteurs de recaptage de neurotransmetteurs de la monoamine
WO2004043921A1 (fr) * 2002-11-11 2004-05-27 Natco Pharma Limited Nouveau procede de preparation de 4-aryl-3-hydroxymethyl-1-methylpiperidines
AP2501A (en) 2003-05-30 2012-10-22 Ranbaxy Lab Ltd Substituted pyrrole derivatives
BRPI0414343A (pt) 2003-09-12 2006-11-07 Pfizer combinações que compreendem ligantes de alfa-2-delta e inibidores da reabsorção de serotonina/noradrenalina
AU2004283196B2 (en) * 2003-09-17 2011-08-25 Janssen Pharmaceutica, N.V. Fused heterocyclic compounds
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
WO2005051919A1 (fr) * 2003-11-26 2005-06-09 Pfizer Products Inc. Derives d'aminopyrazole en tant qu'inhibiteurs de la gsk-3
CA2548917C (fr) 2003-12-11 2014-09-23 Sepracor Inc. Combinaison d'un sedatif et d'un modulateur des neurotransmetteurs, et methodes permettant d'ameliorer la qualite du sommeil et de traiter la depression
WO2005102366A2 (fr) * 2004-04-19 2005-11-03 Philip Maxwell Satow Combinaisons de lithium et utilisations associees
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
US20060063737A1 (en) * 2004-08-18 2006-03-23 Holmdahl Lisa K Liquid paroxetine compositions
US20060039975A1 (en) * 2004-08-20 2006-02-23 Zalman Vilkov Paroxetine formulations
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
PE20061319A1 (es) * 2005-04-22 2006-12-28 Wyeth Corp Cristales formados de clorhidrato de {[(2r)-7-(2,6-diclorofenil)-5-fluoro-2-3-dihidro-1-benzofurano-2-il]metil}amina
JP2008538577A (ja) * 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
MX2007013021A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de benzofuranil-alcanamina y usos de los mismos como agonistas de 5-ht2c.
GT200600164A (es) 2005-04-22 2007-03-14 Derivados de dihidrobenzofuranos y usos de los mismos
US20060264637A1 (en) * 2005-05-16 2006-11-23 Thippannachar Vijayavitthal M Preparation of paroxetine hydrochloride hemihydrate
EP1904843A2 (fr) 2005-07-08 2008-04-02 Braincells, Inc. Methodes destinees a identifier des agents et des conditions modulant la neurogenese
KR101521405B1 (ko) * 2005-07-19 2015-05-18 아제반 파마슈티칼스, 인코퍼레이티드 베타-락타민 페닐알라닌, 시스테인 그리고 세린 바소프레신 길항물질
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1948599A1 (fr) 2005-11-08 2008-07-30 Ranbaxy Laboratories Limited Procede de preparation de sel hemicalcique d acide (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxymethylphenylamino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoique
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
JP2009531435A (ja) * 2006-03-24 2009-09-03 ワイス うつ病の治療用の新規な治療組み合わせ
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
EP2021000A2 (fr) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenèse par modulation de l'angiotensine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
US7998971B2 (en) 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
US20080167363A1 (en) * 2006-12-28 2008-07-10 Braincells, Inc Modulation of Neurogenesis By Melatoninergic Agents
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2008086483A2 (fr) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation de la neurogenèse en utilisant du modafinil
BRPI0814294A2 (pt) 2007-07-19 2015-02-03 Metabolex Inc Agonistas de receptor heterocíclico ligado a n para o tratamento do diabetes e de desordens metabólicas.
CA2698808A1 (fr) 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthese de benzo[d][1,3]dioxoles et de catechols deuteries, ainsi que de leurs derives
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
WO2009128058A1 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
MX2010013876A (es) * 2008-06-20 2011-03-04 Metabolex Inc Agonistas de arilo grpr119 y sus usos .
MX2011005089A (es) 2008-11-14 2011-07-29 Theravance Inc Compuestos de 4-[2-(2-fluorofenoximetil)fenil]piperidina.
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
JP5705239B2 (ja) 2010-01-11 2015-04-22 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー セロトニンおよびノルエピネフリン再取込みインヒビターとしての１−（２−フェノキシメチルフェニル）ピペラジン化合物
JP5769348B2 (ja) * 2010-03-22 2015-08-26 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー １−（２−フェノキシメチルヘテロアリール）ピペリジン化合物および１−（２−フェノキシメチルヘテロアリール）ピペラジン化合物
WO2011163090A1 (fr) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions de 5-éthyl-2-{4-[4-(4-tétrazol-1-yl-phénoxyméthyl)-thiazol-2-yl]-pipéridin-1-yl}-pyrimidine
AU2011272738B2 (en) 2010-07-01 2015-08-20 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
BR112013023810A2 (pt) 2011-03-17 2016-12-13 Lupin Ltd composições farmacêuticas de liberação controlada de inibidores seletivos da recaptação de serotonina
AU2013216123B2 (en) 2012-01-31 2016-10-20 Eisai R&D Management Co., Ltd. Paroxetine derivative
SG11201608064WA (en) 2014-03-28 2016-10-28 Azevan Pharmaceuticals Inc Compositions and methods for treating neurodegenerative diseases
JP2019527693A (ja) 2016-08-03 2019-10-03 サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物
JP2020534274A (ja) 2017-09-15 2020-11-26 アゼヴァン ファーマシューティカルズ，インコーポレイテッド 脳損傷を治療するための組成物及び方法
WO2023102477A1 (fr) * 2021-12-02 2023-06-08 The Johns Hopkins University Inhibiteurs à restriction périphérique et luminale du transporteur de la sérotonine en tant que traitements pour des troubles de la motilité gastro-intestinale et de l'axe intestin-cerveau

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2976291A (en) * 1961-03-21 Ethers of z
US3178438A (en) * 1963-02-06 1965-04-13 Sterling Drug Inc 2-benzyl-3-hydroxy and lower alkoxy piperidines

Also Published As

Publication number Publication date
DE2404113A1 (de) 1974-08-08
JPS49101385A (fr) 1974-09-25
NO144568B (no) 1981-06-15
NL7401189A (fr) 1974-08-01
ES8707224A3 (es) 1987-07-16
FR2215233A1 (fr) 1974-08-23
NL179187C (nl) 1986-08-01
NO740272L (no) 1974-07-31
NL930003I2 (nl) 1994-03-01
IT1054157B (it) 1981-11-10
JPS5946216B2 (ja) 1984-11-10
ES422734A1 (es) 1976-04-01
DK149843C (da) 1987-06-15
HK13081A (en) 1981-04-10
JPS58174363A (ja) 1983-10-13
CA1038390A (fr) 1978-09-12
LU88398I2 (fr) 1994-05-04
ATA69674A (de) 1976-04-15
LU69264A1 (fr) 1974-04-10
IE38801L (en) 1974-07-30
FI57932C (fi) 1980-11-10
AT333759B (de) 1976-12-10
BE810310A (fr) 1974-05-16
DK149843B (da) 1986-10-13
US4007196A (en) 1977-02-08
IE38801B1 (en) 1978-06-07
NL179187B (nl) 1986-03-03
PH10383A (en) 1977-03-02
SE401827B (sv) 1978-05-29
US3912743A (en) 1975-10-14
JPS5948826B2 (ja) 1984-11-29
ES556013A0 (es) 1987-07-16
DE2404113C2 (de) 1985-07-11
NO144568C (no) 1981-09-23
CH592059A5 (fr) 1977-10-14
GB1422263A (en) 1976-01-21
FI57932B (fi) 1980-07-31

Similar Documents

Publication Publication Date Title
FR2215233B1 (fr)
AR201758A1 (fr)
AU476761B2 (fr)
AU465372B2 (fr)
AR201235Q (fr)
AR201231Q (fr)
AU474838B2 (fr)
AU465453B2 (fr)
AU471343B2 (fr)
AU465434B2 (fr)
AU450229B2 (fr)
AU476714B2 (fr)
AR201229Q (fr)
AU476696B2 (fr)
AU466283B2 (fr)
AR199451A1 (fr)
AU477823B2 (fr)
AU461342B2 (fr)
AR195311A1 (fr)
AR210729A1 (fr)
AR196382A1 (fr)
AR197627A1 (fr)
AR200256A1 (fr)
AU476873B1 (fr)
AR201432A1 (fr)

Legal Events

Date Code Title Description
CL Concession to grant licences
CD Change of name or company name
TP Transmission of property
CC Supplementary protection certificate (spc) laid open to the public (law of 25 june 1990)

Free format text: 92C0485, 920624

CB Supplementary protection certificate (spc) granted (law of 25 june 1990)

Free format text: 92C0485, 740129

CL Concession to grant licences